+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Veterinary Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4852018
  • Report
  • September 2018
  • Region: Global
  • 213 pages
  • Transparency Market Research
1 of 2

Global Veterinary Vaccines Market: Overview

Vaccines are products designed to trigger immune response to fight future infection. Vaccination can prevent many pet illness and avoid costly treatments of diseases that can be prevented. The global veterinary vaccines market is expanding at a significant pace due to factors such as new technological advances in vaccines development, continuous development of drug resistance by pathogens, and emergence of new diseases.

The global veterinary vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on technology, animal, and region. A detailed qualitative analysis of drivers, restraints, and opportunities has been provided in the market overview section. Additionally, the section comprises a competitive matrix and company profiles to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by geography and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global veterinary vaccines market.

Global Veterinary Vaccines Market: Key Segments

In terms of technology, the global veterinary vaccines market has been segmented into inactivated vaccines, conjugate vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines. In terms of animal, the global veterinary vaccines market has been classified into companion animal vaccines and livestock animal vaccines. The technology segment has been analyzed based on different types of vaccines uses to treat and prevent different animal diseases in various regions. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Veterinary Vaccines Market: Regional Outlook

In terms of geography, the global veterinary vaccines market has been segmented into five major regions and key countries/sub-regions in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the period from 2018 to 2026, considering 2017 as the base year. The research study also provides the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the market in terms of various attributes such as company overview, financial overview, devices portfolios, business strategies, and recent developments. Major companies profiled in the global veterinary vaccines market include Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), Ceva Santé Animale, Virbac, Biovac, Neogen Corporation, and ImmuCell Corporation.

Note: Product cover images may vary from those shown
2 of 2
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Veterinary Vaccines Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Veterinary Vaccines Market Analysis and Forecasts, 2016-2026
4.3.1. Market Revenue Projection (US$ Mn)

Chapter 5. Market Outlook
5.1. White Space Analysis
5.2. Disease Outbreak Globally : Livestock Animal Disease
5.3. Main (Vector Borne Disease) VBDs affecting livestock
5.4. Animal Population (Mn), by Key Country in 2017
5.5. Top Ten Countries with Highest Number of Vets and Vet Clinics, 2016
5.6. Pet Ownership (%) by Key Country, 2016
5.7. Key Merger & Acquisition in Animal Health Industry
5.8. Regulatory Scenario by Region

Chapter 6. Global Veterinary Vaccines Market Analysis and Forecasts, by Technology
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Technology, 2017-2026
6.3.1. Inactivated Vaccines
6.3.2. Conjugate Vaccines
6.3.3. Live Attenuated Vaccines
6.3.4. Toxoid Vaccines
6.3.5. Other Vaccines
6.4. Market Attractiveness, by Technology

Chapter 7. Global Veterinary Vaccines Market Analysis and Forecasts, by Animal
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Animal, 2017-2026
7.3.1. Livestock Animal Vaccines
7.3.2. Companion Animal Vaccines
7.4. Market Attractiveness, by Animal

Chapter 8. Global Veterinary Vaccines Market Analysis and Forecasts, by Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region

Chapter 9. North America Veterinary Vaccines Market Analysis and Forecast
9.1. Market Value Forecast, by Country, 2017-2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Technology, 2017-2026
9.3. Market Value Forecast, by Technology, 2016-2026
9.3.1. Inactivated Vaccines
9.3.2. Conjugate Vaccines
9.3.3. Live Attenuated Vaccines
9.3.4. Toxoid Vaccines
9.3.5. Other Vaccines
9.4. Market Value Share Analysis, by Animal, 2017-2026
9.5. Market Value Forecast, by Animal, 2016-2026
9.5.1. Livestock Animal Vaccines
9.5.2. Companion Animal Vaccines
9.6. Market Attractiveness Analysis
9.6.1. By Country
9.6.2. By Technology
9.6.3. By Animal

Chapter 10. Europe Veterinary Vaccines Market Analysis and Forecast
10.1. Market Value Forecast, by Country/Sub-region, 2017-2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Technology, 2017-2026
10.3. Market Value Forecast, by Technology, 2016-2026
10.3.1. Inactivated Vaccines
10.3.2. Conjugate Vaccines
10.3.3. Live Attenuated Vaccines
10.3.4. Toxoid Vaccines
10.3.5. Other Vaccines
10.4. Market Value Share Analysis, by Animal, 2017-2026
10.5. Market Value Forecast, by Animal, 2016-2026
10.5.1. Livestock Animal Vaccines
10.5.2. Companion Animal Vaccines
10.6. Market Attractiveness Analysis
10.6.1. By Country/Sub-region
10.6.2. By Technology
10.6.3. By Animal

Chapter 11. Asia Pacific Veterinary Vaccines Market Analysis and Forecast
11.1. Market Value Forecast, by Country/Sub-region, 2017-2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of Asia Pacific
11.2. Market Value Share Analysis, by Technology, 2017-2026
11.3. Market Value Forecast, by Technology, 2016-2026
11.3.1. Inactivated Vaccines
11.3.2. Conjugate Vaccines
11.3.3. Live Attenuated Vaccines
11.3.4. Toxoid Vaccines
11.3.5. Other Vaccines
11.4. Market Value Share Analysis, by Animal, 2017-2026
11.5. Market Value Forecast, by Animal, 2016-2026
11.5.1. Livestock Animal Vaccines
11.5.2. Companion Animal Vaccines
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Technology
11.6.3. By Animal

Chapter 12. Latin America Veterinary Vaccines Market Analysis and Forecast
12.1. Market Value Forecast, by Country/Sub-region, 2017-2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of Latin America
12.2. Market Value Share Analysis, by Technology, 2017-2026
12.3. Market Value Forecast, by Technology, 2016-2026
12.3.1. Inactivated Vaccines
12.3.2. Conjugate Vaccines
12.3.3. Live Attenuated Vaccines
12.3.4. Toxoid Vaccines
12.3.5. Other Vaccines
12.4. Market Value Share Analysis, by Animal, 2017-2026
12.5. Market Value Forecast, by Animal, 2016-2026
12.5.1. Livestock Animal Vaccines
12.5.2. Companion Animal Vaccines
12.6. Market Attractiveness Analysis
12.6.1. By Country/Sub-region
12.6.2. By Technology
12.6.3. By Animal

Chapter 13. Middle East and Africa Veterinary Vaccines Market Analysis and Forecast
13.1. Market Value Forecast, by Country/Sub-region, 2017-2026
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Technology, 2017-2026
13.3. Market Value Forecast, by Technology, 2016-2026
13.3.1. Inactivated Vaccines
13.3.2. Conjugate Vaccines
13.3.3. Live Attenuated Vaccines
13.3.4. Toxoid Vaccines
13.3.5. Other Vaccines
13.4. Market Value Share Analysis, by Animal, 2017-2026
13.5. Market Value Forecast, by Animal, 2016-2026
13.5.1. Livestock Animal Vaccines
13.5.2. Companion Animal Vaccines
13.6. Market Attractiveness Analysis
13.6.1. By Country/Sub-region
13.6.2. By Technology
13.6.3. By Animal

Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Eli Lilly and Company
14.1.2. Boehringer Ingelheim GmbH
14.1.3. Merck Animal Health
14.1.4. Virbac
14.2. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
14.2.1. Boehringer Ingelheim GmbH (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Merck Animal Health (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Zoetis Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Eli Lilly and Company (Elanco Animal Health) (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Bayer AG (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Ceva Santé Animale. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. Virbac (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Biovac (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Neogen Corporation (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Immucell Corporation (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll